Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Farmers Insurance
Express Scripts
Citi
Mallinckrodt
Fuji
Deloitte
Argus Health

Generated: April 19, 2018

DrugPatentWatch Database Preview

CAYSTON Drug Profile

« Back to Dashboard

Which patents cover Cayston, and when can generic versions of Cayston launch?

Cayston is a drug marketed by Gilead and is included in one NDA. There are four patents protecting this drug.

This drug has forty-nine patent family members in eighteen countries.

The generic ingredient in CAYSTON is aztreonam. There are eight drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the aztreonam profile page.
Summary for CAYSTON
Drug patent expirations by year for CAYSTON
Medical Subject Heading (MeSH) Categories for CAYSTON
Synonyms for CAYSTON
(2S,3S)-3-((Z)-2-(2-ammoniothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)imino)acetamido)-2-methyl-4-oxoazetidine-1-sulfonate
(2S,3S)-3-({(2Z)-2-(2-ammonio-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]ethanoyl}amino)-2-methyl-4-oxoazetidine-1-sulfonate
(2S,3S)-3-({(2Z)-2-(2-ammonio-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]ethanoyl}amino)-2-methyl-4-oxoazetidine-1-sulfonate(aztreonam)
(2S,3S)-3-[(2Z)-2-(2-azaniumyl-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetamido]-2-methyl-4-oxoazetidine-1-sulfonate
(2S,3S)-3-[[(2Z)-2-(2-ammonio-4-thiazolyl)-2-(2-carboxypropan-2-yloxyimino)-1-oxoethyl]amino]-2-methyl-4-oxo-1-azetidinesulfonate
(2S,3S)-3-[[(2Z)-2-(2-azaniumyl-1,3-thiazol-4-yl)-2-(2-methyl-1-oxidanyl-1-oxidanylidene-propan-2-yl)oxyimino-ethanoyl]amino]-2-methyl-4-oxidanylidene-azetidine-1-sulfonate
(Z)-2-((((2-Amino-4-thiazolyl)(((2S,3S)-2-methyl-4-oxo-1-sulfo-3-azetidinyl)carbamoyl)methylene)amino)oxy)-2-methylpropionic acid
(Z)-2-[[[(2-Amino-4-thiazolyl)[[(2S,3S)-2-methyl-4-oxo-1-sulfo-3- azetidinyl]carbamoyl]methylene]amino]oxy]-2-methylpropionic acid
[2S-[2alpha,3beta(Z)]]-2-[[[1-(2-Amino-4-thiazolyl)-2-[(2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino]-2-oxoethylidene]amino]oxy]-2-methylpropanoic acid
110A380
2-((((E)-1-(2-aminothiazol-4-yl)-2-(((2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)-2-methylpropanoic acid
2-((((Z)-1-(2-aminothiazol-4-yl)-2-(((2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)-2-methylpropanoic acid
2-(((Z)-(1-(2-Aminothiazol-4-yl)-2-(((2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)-2-methylpropanoic acid
2-({[(1Z)-1-(2-amino-1,3-thiazol-4-yl) -2- {[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino} -2- oxoethylidene]amino}oxy)-2-methylpropanoic acid
2-({[(1Z)-1-(2-amino-1,3-thiazol-4-yl)-2-{[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino}-2-oxoethylidene]amino}oxy)-2-methylpropanoic acid
2-[(Z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxy-2-methylpropanoic acid
2-[(Z)-[1-(2-aminothiazol-4-yl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfo-azetidin-3-yl]amino]-2-oxo-ethylidene]amino]oxy-2-methyl-propanoic acid
2-[[(Z)-[1-(2-Amino-4-thiazolyl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfo-3-azetidinyl]amino]-2-oxoethylidene]amino]oxy]-2-methylpropionic Acid
2-[1-(2-Amino-thiazol-4-yl)-1-((2S,3S)-2-methyl-4-oxo-1-sulfo-azetidin-3-ylcarbamoyl)-meth-(Z)-ylideneaminooxy]-2-methyl-propionic acid
78110-38-0
A839338
AB2000129
AC-4330
AC1NX3U2
AK-41883
AKOS015840157
AKOS015961777
AKOS026750006
Ambap78110-38-0
AN-12074
Antibiotic squibb 26,776
AS-13760
Az-threonam
Azactam
Azactam (TN)
AZACTAM IN PLASTIC CONTAINER
Azetreonam
Azonam
Azthreonam
Aztreon
aztreonam
Aztreonam (Azactam, Cayston)
Aztreonam (JP17/USP/INN)
Aztreonam [USAN:INN:BAN:JAN]
Aztreonam [USAN:USP:INN:BAN:JAN]
Aztreonam lysine
Aztreonam, analytical standard
Aztreonam, pharmaceutical secondary standard; traceable to USP
Aztreonam, United States Pharmacopeia (USP) Reference Standard
Aztreonamum
Aztreonamum [Latin]
BC208259
BCP9000372
BCPP000356
BDBM50240480
BIDD:GT0765
BPBio1_000121
BRD-K62607865-001-03-0
BRN 3577211
BSPBio_000109
C06840
C13H17N5O8S2
CC-24234
CCG-220185
CHEBI:161680
CHEMBL158
Corus 1020
CS-1902
D00240
D0F2XV
DB00355
Dynabiotic
E-Aztreonam
EINECS 278-839-9
G2B4VE5GH8
HMS1568F11
HMS2090K09
HMS2095F11
HY-B0129
J10266
LS-121219
MFCD00072145
MLS003915628
MLS006011974
MolPort-003-886-345
Monobactam
Monobactam, SQ 26776, Squibb 26776, Aztreonam
Monobactam;SQ 26776;Squibb 26776;Azactam;Cayston
NCGC00179656-01
Nebactam
NSC 646279
NSC-646279
NSC646279
Prestwick_914
Prestwick2_000185
Prestwick3_000185
Primbactam
Propanoic acid, 2-(((1-(2-amino-4-thiazolyl)-2-((2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino)-2-oxoethylidene)amino)oxy)-2-methyl-, (2S-(2-alpha,3-beta(Z)))-
Propanoic acid, 2-(((1-(2-amino-4-thiazolyl)-2-((2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino)-2-oxoethylidene)amino)oxy)-2-methyl-, (2S-(2alpha,3beta(Z)))-
Propanoic acid, 2-[[(Z)-[1-(2-amino-4-thiazolyl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfo-3-azetidinyl]amino]-2-oxoethylidene]amino]oxy]-2-methyl-
PubChem13620
RP18114
S1505
SCHEMBL37511
SMR002204030
SMR004703537
SO-26776
SQ 26,776
SQ 26776
SQ-26,776
SQ-26776
Squibb 26,776
Squibb 26776
SR-01000841814
SR-01000841814-2
UNII-G2B4VE5GH8
Urobactam
WZPBZJONDBGPKJ-VEHQQRBSSA-N
ZINC12503091

US Patents and Regulatory Information for CAYSTON

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gilead CAYSTON aztreonam FOR SOLUTION;INHALATION 050814-001 Feb 22, 2010 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Gilead CAYSTON aztreonam FOR SOLUTION;INHALATION 050814-001 Feb 22, 2010 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Gilead CAYSTON aztreonam FOR SOLUTION;INHALATION 050814-001 Feb 22, 2010 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Gilead CAYSTON aztreonam FOR SOLUTION;INHALATION 050814-001 Feb 22, 2010 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for CAYSTON

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,841,286 Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections ➤ Try a Free Trial
9,345,663 Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections ➤ Try a Free Trial
9,533,000 Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections ➤ Try a Free Trial
6,660,249 Inhalable dry powder aztreonam for treatment and prevention of pulmonary bacterial infections ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for CAYSTON

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB11/049 United Kingdom ➤ Try a Free Trial PRODUCT NAME: AZTREONAM LYSINE; REGISTERED: UK EU/1/09/543/001 20090921
00492 Netherlands ➤ Try a Free Trial PRODUCT NAME: AZTREONAM, NIET IN EEN SAMENSTELLING MET ARGININE, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT VAN AZTREONAM, ANDERS DAN EEN ARGININEZOUT, IN HET BIJZONDER ALS AZTREONAMLYSINE; REGISTRATION NO/DATE: EU/1/09/543/001 20090921
1353647/01 Switzerland ➤ Try a Free Trial PRODUCT NAME: AZTREONAMLYSIN; REGISTRATION NO/DATE: SWISSMEDIC 59389 06.12.2010
11/024 Ireland ➤ Try a Free Trial PRODUCT NAME: AZTREONAM LYSINE; REGISTRATION NO/DATE: EU/1/09/543/001 20090923
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
US Department of Justice
Chinese Patent Office
Daiichi Sankyo
Dow
Baxter
McKinsey
Cerilliant
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.